

Dear Editor,

Reviewed by 02873420

Title: Triiodothyronine (T3) and breast cancer

Author: Authors: Maria Teresa De Sibio, Miriane de Oliveira, Fernanda Cristina Fontes Moretto, Regiane Marques Castro Olimpio, Sandro Jos é Conde, Aline Carbonera Luvizon, C édia Regina Nogueira.

Name of Journal: World Journal of Clinical Oncology

ESPS Manuscript NO: 8910

Comments To Authors

Your article is a very good review of the relationship between T3 and breast cancer. It is well researched and comprehensive. The figure is clear, and the flow of ideas is logical. My comments are the following: -The article needs minor language changes to improve its readability. I recommend that a scientist with an excellent command of English polishes it. For example, Oxford commas are often missing. I also suggest replacing the word "important" with a more specific one, e.g "enhances", "facilitates", "determines", etc. The same applies to the term "due" which can be replaced with better alternatives. -Under the Core tip section, you mention "an 26% increase in relation to current levels". Is this an increase in the absolute number, prevalence or incidence of breast Ca? As it is, the sentence can be confusing -A note is needed in order to clarify the clinical implications of the topic. In short, why do we need to understand the relationship between the two? This element is of paramount importance to the reader, and therefore should be clearly stated. You do allude to it in a scattered matter, but I believe that one or two sentences on the clinical benefits of deciphering this controversy will solidify your manuscript.

Changes in the article are highlighted in yellow.

Reviewer's Responses to Questions

1-I recommend that a scientist with an excellent command of English polishes it. For example, Oxford commas are often missing. I also suggest replacing the word "important" with a more specific one, e.g "enhances", "facilitates", "determines", etc. The same applies to the term "due" which can be replaced with better alternatives.

R: We agree with the reviewer and the English was revised by *BioMed Proofreading* (A BioMed Proofreading, LLC)

2-Under the Core tip section, you mention "an 26% increase in relation to current levels". Is this an increase in the absolute number, prevalence or incidence of breast Ca? As it is, the sentence can be confusing -A note is needed in order to clarify the clinical implications of the topic.

R: We agree with the reviewer and added the current incidence in Core Tip (page 4 line 61-77).

Dear Editor,

Reviewed by 01339879

Title: Triiodothyronine (T3) and breast cancer

Author: Authors: Maria Teresa De Sibio, Miriane de Oliveira, Fernanda Cristina Fontes Moretto, Regiane Marques Castro Olimpio, Sandro Jos é Conde, Aline Carbonera Luvizon, C édia Regina Nogueira.

Name of Journal: World Journal of Clinical Oncology

ESPS Manuscript NO: 8910

Comments To Authors

THIS IS AN INTERESTING SHORT REVIEW. Areas of concern are: Measurement of T4,T3,FT4,FT3 have been evolving over the decades and it is now clear that direct analogue immunoassays(IA's) for FT3 and FT4 are poor as are IA's for T3. Reliable data would require reassessment using equilibrium dialysis or ultrafiltration (to separate the binding proteins)followed by mass spectrometric measurement for quantitation of FT4/FT3 and also mass spec is needed for accurate measurement of T3.In general IA's are poor at both low and high thyroid hormone levels. REFERENCE TO THESE CONCERNS NEED TO BE INCLUDED BY THE AUTHORS.See CCA 2014;430:121-4.Also Advances in Clinical Chemistry 2013:61;127-152. And Clin Chem 2011 Jan;57(1):122-7. Finally Endocrine Practice 2014 Jonklaas et al

Reviewer's Responses to Questions

We agree with the reviewer and added the the reference suggested (page 6 line 108-115 and page 14 line 288-291).